Fever, uncontrolled bleeding or severe breathlessness need emergency care today. With low white cells and platelets, infection and bleeding can escalate quickly. Do not wait until morning.
The bone marrow produces blood cells that are abnormal and fail to mature properly. Counts fall despite a marrow that may look busy, and in a proportion of patients the condition progresses to acute leukaemia.
Everything in this condition turns on risk scoring. Lower-risk disease is managed for years with supportive treatment; higher-risk disease needs prompt action, and transplant is the only curative option.
The marrow's stem cells acquire genetic changes that impair their ability to mature into normal blood cells. The result is a marrow that is often full of cells but produces too few functional ones — anaemia, low white cells and low platelets, in varying combinations.
It is largely a disease of older people, though it occurs at any age and follows previous chemotherapy or radiotherapy in some patients. In a proportion the abnormal clone accumulates further changes and transforms into acute myeloid leukaemia.
The critical concept is risk stratification. The revised International Prognostic Scoring System combines the blood counts, the percentage of immature cells in the marrow, and the cytogenetic abnormalities present, to place a patient in a risk category. That category determines everything — whether to observe, to treat supportively, to give drug therapy, or to proceed to transplant.
The most important practical point is that lower-risk and higher-risk disease are managed almost oppositely. A patient with lower-risk disease may live for years with transfusion support and no aggressive treatment at all. A patient with higher-risk disease has limited time and should be assessed for transplant promptly.
Being told you have myelodysplastic syndrome tells you very little on its own. The IPSS-R risk score, calculated from your blood counts, the percentage of blasts in the marrow and the cytogenetic findings, determines whether the right course is observation, supportive care, drug treatment or transplant — and those are very different paths. If nobody has given you a risk category, ask for it specifically, and make sure cytogenetic testing has actually been performed on the marrow sample, because the score cannot be calculated without it.
The marrow, with cytogenetics, is what allows risk to be scored.
Without cytogenetic results from the marrow, a risk score cannot be calculated, and without a risk score nobody can tell you whether you need a transplant, a drug, or simply monitoring. If your marrow report has no cytogenetics, ask whether the sample was sent for it and whether it can be repeated. Send the marrow report, counts over time, cytogenetics and any molecular results, plus your transfusion history.
Lower-risk and higher-risk disease are managed in almost opposite ways.
Transfusion for symptomatic anaemia, erythropoietin to reduce transfusion need, antibiotics for infection, and monitoring. Many patients with lower-risk disease are managed this way for years with a good quality of life and no aggressive treatment at all. Iron chelation is added where transfusion dependence is prolonged.
Lenalidomide is highly effective in patients with a specific chromosomal abnormality, deletion 5q, frequently removing the need for transfusion entirely. Newer agents help selected patients with ring sideroblasts. These depend entirely on the cytogenetic and molecular findings, which is why that testing matters.
Azacitidine or decitabine slow progression and improve survival in higher-risk disease. They are given in cycles, take several months to show benefit, and are often used to control disease while transplant is arranged — or as the main treatment where transplant is not possible.
The only treatment that can cure myelodysplastic syndrome. It is offered to patients with higher-risk disease who are fit enough, with a matched sibling, half-matched family member or unrelated donor. Reduced-intensity conditioning has extended it to older patients who could not have tolerated full conditioning.
This decides between observation, supportive care, drugs and transplant. It requires cytogenetics.
Reduced-intensity conditioning has widened who can be transplanted, but organ function and general fitness still determine feasibility.
HLA type siblings early where higher-risk disease is identified, since the timeline matters.
If your disease is lower risk and you feel well, we will tell you that transplant is not indicated. Transplanting lower-risk disease exposes patients to substantial risk for no benefit.
A rising blast count or rapidly falling counts suggests transformation and needs prompt local assessment rather than a planned trip.
Photographs taken on your phone are fine. Reports in Arabic, Russian or Bengali are fine — we translate them ourselves.
The IPSS-R combines your blood counts, the percentage of blasts in the marrow and your cytogenetic findings into a risk category. It determines whether the right course is monitoring, supportive care, drug treatment or transplant — and those paths are very different. If nobody has told you your category, ask for it specifically.
It depends entirely on your risk category and your fitness. Higher-risk disease in a patient fit enough for the procedure is where transplant is indicated, because it is the only curative option. Lower-risk disease is generally managed with supportive care for years, and transplanting it exposes patients to serious risk for no benefit.
In a proportion of patients, yes, and the likelihood is reflected in the risk score. Higher-risk disease progresses more often and more quickly. This risk of transformation is a large part of why higher-risk patients are assessed for transplant promptly rather than observed.
Because it is required to calculate the risk score, and because specific abnormalities have specific treatments — deletion 5q responds particularly well to lenalidomide, for instance. Without cytogenetics, your assessment is incomplete and treatment decisions are being made on partial information.
Possibly. Reduced-intensity conditioning uses gentler preparative treatment and has extended transplant to patients in their sixties and seventies who could not tolerate full conditioning. Fitness, organ function and other medical conditions matter far more than the number itself. Send your reports and we will give you a proper answer.
It accumulates and can damage the heart and liver over years, exactly as in thalassemia. In transfusion-dependent patients with lower-risk disease and a reasonable life expectancy, iron chelation is worth considering. It also matters before transplant, since liver iron affects how well conditioning is tolerated.
Send the bone marrow report with cytogenetics and your blood counts over time. Without cytogenetics a risk score cannot be calculated, and without that nobody can advise you properly.
Your reports go directly to our medical team. We do not share your records with hospitals until you tell us to.
WhatsApp +91 83035 86344 · Phone +91 83035 86344 · Email tibhind@gmail.com
Coordinators available 9:00–20:00 IST. We speak Arabic, English, Russian and Bengali.